Benevolo Savelli Corrado, Clerico Michele, Botto Barbara, Secreto Carolina, Cavallo Federica, Dellacasa Chiara, Busca Alessandro, Bruno Benedetto, Freilone Roberto, Cerrano Marco, Novo Mattia
Hematology Division, A.O.U. Città della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy.
Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy.
Cancers (Basel). 2023 Dec 21;16(1):46. doi: 10.3390/cancers16010046.
In the last decade, anti-CD19 CAR-T cell therapy has led to a treatment paradigm shift for B-cell non-Hodgkin lymphomas, first with the approval for relapsed/refractory (R/R) large B-cell lymphomas and subsequently for R/R mantle cell and follicular lymphoma. Many efforts are continuously being made to extend the therapeutic setting in the lymphoma field. Several reports are supporting the safety and efficacy of CAR-T cells in patients with central nervous system disease involvement. Anti-CD30 CAR-T cells for the treatment of Hodgkin lymphoma are in development and early studies looking for the optimal target for T-cell malignancies are ongoing. Anti-CD19/CD20 and CD19/CD22 dual targeting CAR-T cells are under investigation in order to increase anti-lymphoma activity and overcome tumor immune escape. Allogeneic CAR product engineering is on the way, representing a rapidly accessible 'off-the-shelf' and potentially more fit product. In the present manuscript, we will focus on recent advances in CAR-T cell therapy for lymphomas, including new settings and future perspectives in the field, reviewing data reported in literature in the last decade up to October 2023.
在过去十年中，抗CD19嵌合抗原受体T细胞（CAR-T）疗法引发了B细胞非霍奇金淋巴瘤治疗模式的转变，首先获批用于复发/难治性（R/R）大B细胞淋巴瘤，随后又获批用于R/R套细胞淋巴瘤和滤泡性淋巴瘤。人们不断努力扩大CAR-T细胞疗法在淋巴瘤领域的治疗范围。多项报告支持了CAR-T细胞在合并中枢神经系统疾病患者中的安全性和有效性。用于治疗霍奇金淋巴瘤的抗CD30 CAR-T细胞正在研发中，针对T细胞恶性肿瘤最佳靶点的早期研究也在进行。为了增强抗淋巴瘤活性并克服肿瘤免疫逃逸，抗CD19/CD20和CD19/CD22双靶点CAR-T细胞也在研究中。同种异体CAR产品工程正在推进，有望成为一种快速可得的“现货”产品，且可能更具适用性。在本手稿中，我们将重点关注CAR-T细胞疗法治疗淋巴瘤的最新进展，包括该领域的新治疗范围和未来前景，回顾截至2023年10月过去十年文献报道的数据。
